Inventor
PLAYER MARK R
US32 patents
⚠️ This page may combine multiple inventors who share the name “PLAYER MARK R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
24 patentsUS7608622B2Oct 27, 2009
Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
JANSSEN PHARMACEUTICA NV53 citations96
US7790724B2Sep 7, 2010
c-fms kinase inhibitors
JANSSEN PHARMACEUTICA NV26 citations90
US9067898B1Jun 30, 2015
Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV13 citations84
US7829584B2Nov 9, 2010
Pyridines and pyridine N-oxides as modulators of thrombin
JANSSEN PHARMACEUTICA NV12 citations81
US9920040B2Mar 20, 2018
GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV2 citations73
US9908873B2Mar 6, 2018
GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV2 citations73
US9856245B2Jan 2, 2018
GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV2 citations73
US9193736B2Nov 24, 2015
PDE 10a inhibitors for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV7 citations72
US7326788B2Feb 5, 2008
Quinolinone derivatives as inhibitors of c-fms kinase
JANSSEN PHARMACEUTICA NV8 citations71
US9718820B2Aug 1, 2017
Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators
JANSSEN PHARMACEUTICA NV1 citations60
US7951829B2May 31, 2011
Benzimidazole modulators of VR1
JANSSEN PHARMACEUTICA NV6 citations60
US10988433B2Apr 27, 2021
Cyclohexyl GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations52
US10662170B2May 26, 2020
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations52
US10131648B2Nov 20, 2018
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations52
US9790198B2Oct 17, 2017
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations52
US9409915B2Aug 9, 2016
Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
JANSSEN PHARMACEUTICA NV0 citations49
US9023846B2May 5, 2015
Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
JANSSEN PHARMACEUTICA NV0 citations49
US7642270B2Jan 5, 2010
5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
JANSSEN PHARMACEUTICA NV1 citations49
US10106553B2Oct 23, 2018
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations41
US9688642B2Jun 27, 2017
Substituted pyrazines as GPR40 agonists
JANSSEN PHARMACEUTICA NV0 citations41
US9249163B2Feb 2, 2016
PDE10a inhibitors for the treatment of type II diabetes
JANSSEN PHARMACEUTICA NV0 citations40
US7612211B2Nov 3, 2009
Benzimidazole TRPV1 inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
US7446210B2Nov 4, 2008
Factor Xa compounds
JANSSEN PHARMACEUTICA NV0 citations39
US7728003B2Jun 1, 2010
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
JANSSEN PHARMACEUTICA NV0 citations36